Company intelligence / Profile preview

O2nix Bio

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

O2nix Bio is a preclinical-stage biotechnology company developing novel therapies targeting the RNA modification enzyme FTSJ1, implicated in metastatic cancer cell survival. The company is advancing a proprietary platform that leverages insights into tRNA methylation and oxidative stress adaptation in cancer. There are no clinical results reported yet, but preclinical research has demonstrated the role of FTSJ1 in cancer metastasis, providing a scientific rationale for its therapeutic targeting[1][2].

Therapeutic areas: Oncology
Modalities: Prooxidant therapySmall molecule
Industry: Biotech

Partnerships

Synfini

Beyond the preview

Go deeper on O2nix Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on O2nix Bio.

Explore the full profile